Reports Q1 revenue $160.3M, consensus $158.84M. "2023 is off to a positive start as EXPAREL continues to outperform the elective surgery market with expanding utilization across key target markets and all sites of care," said Dave Stack, chairman and chief executive officer of Pacira BioSciences. "The rollout of our 340B pricing program has performed according to plan with volumes expanding within both existing and naive business. For ZILRETTA and iovera degrees , our full field-based team is broadening awareness and we are seeing a significant increase in first-time customers for these complementary and standalone non-opioid solutions for managing osteoarthritis pain."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on PCRX:
- Pacira BioSciences Reports First Quarter 2023 Financial Results
- Pacira to Report First Quarter 2023 Financial Results on Wednesday May 3, 2023
- Pacira price target lowered to $62 from $63 at Piper Sandler
- Pacira BioSciences Partners with The Invited Celebrity Classic – a PGA TOUR Champions Event – to Make iovera° The Official Non-Opioid Pain Management Partner
- Pacira partners with the Invited Celebrity Classic
